# IGHV mutational status

Source: https://onco.cc/terms/ighv-status/  
OnCo record `ighv-status` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Whether the leukaemia's antibody gene has been 'edited' by the immune system. Unmutated means faster-growing CLL and a bigger benefit from targeted drugs over chemotherapy.

## Summary

IGHV genes with <2% deviation from germline are 'unmutated' (~40-50% of CLL) and predict shorter time to treatment and poor response to chemoimmunotherapy (FCR). BTK inhibitors and venetoclax combinations largely erase the difference for progression, and IGHV status is a stratification factor in every modern CLL trial (CLL13, AMPLIFY). Mutated-IGHV patients still achieve the longest remissions after fixed-duration therapy.

## Fields

- Kind: Term
- Last checked: 2026-09-07

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Chronic_lymphocytic_leukemia
- Wikipedia: https://en.wikipedia.org/wiki/Chronic_lymphocytic_leukemia

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [Chronic lymphocytic leukaemia, first treatment](https://onco.cc/cancers/cll-treatment-naive/), [Waldenström macroglobulinaemia](https://onco.cc/cancers/waldenstrom/)
- technologies: [Comprehensive genomic profiling](https://onco.cc/technologies/cgp/)
- trials: [AMPLIFY](https://onco.cc/trials/amplify/), [CLL13 / GAIA](https://onco.cc/trials/cll13-gaia/)
- ideas: [MRD-guided treatment duration in CLL](https://onco.cc/ideas/idea-mrd-guided-stop-cll/)
- key papers: [CLL14: one year of venetoclax plus obinutuzumab instead of chemo-immunotherapy in older, less fit CLL patients](https://onco.cc/key-papers/paper-cll14-venetoclax-obinutuzumab-nejm-2019/)
- terms: [CLL-IPI (chronic lymphocytic leukaemia prognostic index)](https://onco.cc/terms/cll-ipi/)
- institutions: [Northwell Health Cancer Institute](https://onco.cc/institutions/northwell-cancer-institute/)

---
JSON: https://onco.cc/api/v1/entities/ighv-status.json